{
    "nctId": "NCT06611514",
    "briefTitle": "Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause with Previous Breast Cancer",
    "officialTitle": "Effect of Intravaginal Prasterone on Genitourinary Syndrome in Women in Menopause with Previous Breast Cancer or Currently Under Treatment with Endocrine Therapy for Breast Cancer with Aromatase Inhibitor +/- LHRHa",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Women with Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 95,
    "primaryOutcomeMeasure": "Establish subjective improvement in genitourinary symptomatology at intervals marked by the study",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed breast cancer, completely excised\n* Natural or iatrogenic menopausal status\n* No evidence of distant metastasis\n* Self-identified moderate to severe symptoms of genitourinary syndrome\n* Normal kidney and liver function\n* Written Informed Consent signed and dated by patient\n* Negative Papanicolau (Pap) Smear Cytology Test within 1 year prior to enrollment\n\nExclusion Criteria:\n\n* Vaginal or uterine bleeding of unknown origin\n* Current diagnosis of any non-breast malignancy\n* Metastatic disease\n* Currently on chemiotherapy\n* Currently on treatment with tamoxifen\n* Mentally incompetent or evidence of active substance or alcohol abuse\n* Endometrial hyperplasia\n* Pregnancy or lactation\n* Currently use of other vaginal therapy for the same purpose (if present, they have to be stopped 15 days before baseline visit)\n* Clinically significant metabolic or endocrine disease not controlled by medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}